文献速递糖尿病肥胖与代谢综合征

在初级保健中整合模拟禁食饮食方案可减少2型糖尿病患者的用药需求并改善血糖控制:一项12个月随机对照试验

Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-03-28

这项随机、对照、评估者盲法试验纳入100例以二甲双胍为唯一降糖药和/或饮食控制血糖的2型糖尿病患者,随机分为每月5天模拟禁食饮食(FMD)方案联合常规初级保健组(n=51)或仅常规保健组(n=49)。12个月时,FMD组用药效应评分、HbA1c和体重的调整估计治疗效应均显著优于对照组,血糖管理改善比例更高,且在日常临床实践中似乎安全。

要点

  • 每月5天FMD联合常规保健可降低2型糖尿病患者的降糖用药需求(用药效应评分-0.3)。
  • 12个月时FMD组HbA1c较对照组降低3.2 mmol/mol(-0.3%),体重降低3.6 kg。
  • FMD组血糖管理改善者占53%,对照组占8%; deteriorated者分别为23%和59%。

核心结论

  • 在初级保健中整合每月FMD方案可减少以二甲双胍为唯一降糖药和/或饮食控制血糖的2型糖尿病患者的降糖用药需求,在减少用药的同时改善HbA1c,并且在常规临床实践中似乎安全。

研究设计与样本

  • 随机、对照、评估者盲法试验,纳入100例年龄18-75岁、BMI≥27 kg/m2、以二甲双胍为唯一降糖药和/或饮食控制血糖的2型糖尿病患者,随机分为FMD组(n=51)和对照组(n=49)。

主要发现

  • 12个月时,FMD组较对照组的调整估计治疗效应:用药效应评分-0.3(95% CI -0.4, -0.2;p<0.001),HbA1c -3.2 mmol/mol(95% CI -6.2, -0.2)和-0.3%(95% CI -0.6, -0.0;p=0.04),体重-3.6 kg(95% CI -5.2, -2.1;p<0.001)。
  • 血糖管理改善者FMD组53% vs 对照组8%,保持稳定者23% vs 33%,恶化者23% vs 59%(p<0.001)。
  • FMD组8例、对照组10例失访。

关键数值与推荐

  • FMD方案为每月5天周期,作为全科医生常规保健的辅助。
  • 主要结局为12个月时用药效应评分和HbA1c水平的变化。

临床怎么用

  • 对于以二甲双胍为唯一降糖药和/或饮食控制血糖的2型糖尿病患者,在常规初级保健中整合每月FMD方案可减少降糖用药需求并改善HbA1c,且似乎安全。

局限性

  • FMD组8例和对照组10例失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to evaluate the impact on metabolic control of periodic use of a 5-day fasting-mimicking diet (FMD) programme as an adjunct to usual care in people with type 2 diabetes under regular primary care surveillance. METHODS: In this randomised, controlled, assessor-blinded trial, people with type 2 diabetes using metformin as the only glucose-lowering drug and/or diet for glycaemic control were randomised to receive 5-day cycles of an FMD monthly as an adjunct to regular care by their general practitioner or to receive regular care only. The primary outcomes were changes in glucose-lowering medication (as reflected by the medication effect score) and HbA1c levels after 12 months. Moreover, changes in use of glucose-lowering medication and/or HbA1c levels in individual participants were combined to yield a clinically relevant outcome measure ('glycaemic management'), which was categorised as improved, stable or deteriorated after 1 year of follow-up. Several secondary outcome measures were also examined, including changes in body weight. RESULTS: One hundred individuals with type 2 diabetes, age 18-75 years, BMI ≥27 kg/m2, were randomised to the FMD group (n=51) or the control group (n=49). Eight FMD participants and ten control participants were lost to follow-up. Intention-to-treat analyses, using linear mixed models, revealed adjusted estimated treatment effects for the medication effect score (-0.3; 95% CI -0.4, -0.2; p<0.001), HbA1c (-3.2 mmol/mol; 95% CI -6.2, -0.2 and -0.3%; 95% CI -0.6, -0.0; p=0.04) and body weight (-3.6 kg; 95% CI -5.2, -2.1; p<0.001) at 12 months. Glycaemic management improved in 53% of participants using FMD vs 8% of control participants, remained stable in 23% vs 33%, and deteriorated in 23% vs 59% (p<0.001). CONCLUSIONS/INTERPRETATION: Integration of a monthly FMD programme in regular primary care for people with type 2 diabetes who use metformin as the only glucose-lowering drug and/or diet for glycaemic control reduces the need for glucose-lowering medication, improves HbA1c despite the reduction in medication use, and appears to be safe in routine clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT03811587 FUNDING: The project was co-funded by Health~Holland, Top Sector Life Sciences & Health, the Dutch Diabetes Foundation and L-Nutra.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. van den Burg EL, Schoonakker MP, van Peet PG, et al. Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. Diabetologia. 2024. PMID: 38546821. doi:10.1007/s00125-024-06137-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。